Dr Reddy’s Labs Q3 Outcomes: Pharma firm Dr Reddy’s Laboratories on Thursday, January 23 introduced a 2% year-on-year improve in consolidated revenue after tax (PAT) to ₹1,413.3 crore for the quarter ended December 2024 (Q3). The PAT in Q3 of final yr stood at ₹1,378.9 crore.
The income from operations for the stated quarter got here in at ₹8,358.6 crore, recording a 16% YoY leap versus ₹7,214.8 crore posted within the December 2023 quarter.
The expansion was largely pushed by revenues from the not too long ago acquired Nicotine Substitute Remedy(NRT) portfolio, revenues from India and Rising Markets, the corporate stated.
The worldwide generics phase income noticed a 17% YoY improve in Q3 whereas the pharmaceutical companies and energetic substances (API) phase witnessed a 5% development in income.
The earnings earlier than curiosity, tax, depreciation and amortization in Q3 stood at ₹2,298.2 crore as towards ₹2,110.7 crore in the identical quarter final yr and ₹2,280.3 crore within the previous quarter of FY25.
In the meantime, the gross margin for the quarter underneath evaluate was at 58.7%, in step with 58.5% and decrease than 59.6% in Q2 FY25.
The corporate spent ₹6.7 billion on analysis and improvement in Q3 FY25, which was 8% of the revenues. R&D investments are associated to our ongoing improvement efforts throughout complicated generics, peptides, biosimilars, in addition to our novel oncology belongings.
Commenting on the outcomes, Co-Chairman & MD, G V Prasad stated, “We delivered double-digit development aided by our newly acquired NRT enterprise, new launches and improved operational efficiencies. We stay dedicated to addressing affected person wants by advancing healthcare by way of entry, affordability and innovation.”
Efficiency for 9M FY25
The corporate’s topline efficiency for the nine-months ended December was robust, with income rising 15% YoY to ₹24047.5 crore. Nevertheless, revenue witnessed a 5% YoY decline to ₹4060 crore.
The EBITDA for the quarter got here in at ₹6738.4 crore, greater than ₹6429.3 crore posted in the identical quarter of the monetary yr 2023-24.
Dr Reddy’s Labs share worth ended at ₹1289.35, down 0.54% on the BSE.
Disclaimer: The views and proposals above are these of particular person analysts or broking firms, not Mint. We advise traders to verify with licensed consultants earlier than making any funding choices.
